This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 Big-Pharma Stocks With Untapped Potential

BOSTON ( TheStreet) -- Investors seeking steady dividends coupled with inflation-beating share appreciation may want to consider big drugmakers' stocks. They're expected to have as yet unrecognized growth potential from emerging market demand.

Investors are discounting the potential profit contribution from emerging markets because of their recent economic volatility and investors focus on the more dominant U.S. market, while there is also a misperception that operating profit margins coming from such markets are too low to matter, wrote Damien Conover, a Morningstar drug industry analyst, in a research report. "We expect this discount will dissipate as emerging markets' economies stabilize and their sales contribution increases."

Conover estimates that sales from emerging markets will represent 26% of Big Pharma's total sales by 2015, up from 19% in 2011, aided by rapid wealth creation in emerging-market countries that will drive demand for branded pharmaceuticals and a shift in companies' revenue mix as patent losses in developed markets result in their decline as a percentage of total revenue.

Conover cited seven top international drug-company stocks in his report, and they have dividend yields ranging from 2% for the German chemicals conglomerate Bayer (BAYRY) to 6% for drugmaker AstraZeneca (AZN - Get Report).

Here are summaries of the seven biggest international pharmaceutical companies' stocks, arranged in inverse order of the number of analysts' "buy" ratings:

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GSX $0.02 0.00%
ABT $47.49 0.00%
AZN $70.76 0.00%
BMY $65.16 0.00%
JNJ $100.58 0.00%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs